MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.92
+0.05
+0.30%
Opening 15:36 09/23 EDT
OPEN
17.68
PREV CLOSE
16.87
HIGH
18.09
LOW
16.80
VOLUME
149.00K
TURNOVER
--
52 WEEK HIGH
67.08
52 WEEK LOW
8.80
MARKET CAP
99.12M
P/E (TTM)
-1.8361
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Insider Buys Protara Therapeutics Shares
Protara Therapeutics Inc (NASDAQ:TARA) was trading 3.7% higher from the previous closing price. Davis Blaine filed a Form 4 with the SEC on Tuesday, September 22. The insider bought 1,481 shares at an average price of $16.91. After the transaction, the executive's stake in Protara Therapeutics Inc. moved to 1,481 shares.
Benzinga · 4h ago
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the pricing of two concurrent but separate underwritten public
GlobeNewswire · 1d ago
Protara Therapeutics Announces Pricing Of $147.6M Of Securities In Concurrent Public Offerings Of 4.6M Shares At $16.87/Share
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.
Benzinga · 1d ago
Protara Therapeutics prices two offerings
Protara Therapeutics (TARA) priced its two concurrent but separate underwritten public offerings of 4.6M shares for $16.87/share and 4,148 shares of its non-voting Series 1 Convertible Preferred Stock at $16,873.54/share.Each share
Seekingalpha · 1d ago
The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 21)
Benzinga · 1d ago
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that it intends to offer and sell shares of its common stock
GlobeNewswire · 1d ago
Protara Therapeutics proposes common stock and preferred stock offerings
Protara Therapeutics (TARA) plans to offer common stock and series 1 convertible preferred stock in two concurrent but separate transactions. Price, volume and terms not yet disclosed.The proceeds will be used
Seekingalpha · 1d ago
Protara Therapeutics Provides Comparability And US Regulatory Updates For TARA-002 Supporting Advancement In Oncology And Rare Disease Indications
- Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs -   - Reaches Alignment with FDA on Development Path Forward for TARA-002 in Non-Muscle Invasive
Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs -   - Reaches Alignment with FDA on Development Path Forward for TARA-002 in Non-Muscle Invasive · 09/08 11:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TARA. Analyze the recent business situations of Protara Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TARA stock price target is 47.50 with a high estimate of 50.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 49
Institutional Holdings: 7.29M
% Owned: 124.40%
Shares Outstanding: 5.86M
TypeInstitutionsShares
Increased
13
223.80K
New
19
-117.69K
Decreased
4
99.59K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.69%
Pharmaceuticals & Medical Research
-1.07%
Key Executives
Chairman/Director
Luke Beshar
President/Chief Executive Officer/Director
Jesse Shefferman
Chief Financial Officer/IR Contact Officer
Blaine Davis
Senior Vice President
Jacqueline Zummo
Director
Barry Flannelly
Independent Director
Roger Garceau
Independent Director
Richard Levy
Independent Director
Gregory Sargen
Independent Director
Michael Solomon
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TARA
Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Its product pipeline includes TARA 002 and IV choline chloride for injection. TARA 002 is its lead program focused on the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Protara Therapeutics Inc stock information, including NASDAQ:TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.